NASDAQ$LNAI
Lunai Bioworks Inc · Q2 2026 earnings
Q2 2026 earnings · · Investor relations
Briefing
Lunai Bioworks reported Q2 2026, net loss of $1.8M.
For Q2 2026, Lunai Bioworks reported a net loss of $1.8M. Management discusses segment performance, capital allocation, and outlook in the earnings release.
- Net loss $1.8M.
- Lunai Bioworks highlights liquidity, operations, and 2026 priorities.
- Lunai Bioworks highlights liquidity, operations, and 2026 priorities.
Headline financials
Revenue & EPS history
Renovaro · Revenue · Quarterly
$157K
Forward guidance
The release discusses Lunai Bioworks's outlook for upcoming periods, including capital allocation, operating priorities, and market risks, without relying solely on numeric EPS bridges.
Tailwinds
- Lunai Bioworks cites operational execution and demand trends supporting the outlook.
- Balance sheet and liquidity actions aim to fund growth and returns.
Headwinds
- GAAP profitability remained under pressure in Q2 2026.
- Macro, pricing, and input-cost volatility could pressure margins.
- Segment mix and one-time items may affect quarter-to-quarter comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2026
+2.0%
Avg return
Earnings day
+2.2%
Avg return
5 days after
+6.9%
Avg return
30 days after
44%
16 / 36 earnings
Positive
+36.6%
Q4 2024
Best reaction
-17.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | -7.3% | -18.5% | +9.3% | |
| Q2 2026 | -9.1% | -25.7% | -47.5% | |
| Q1 2026 | +5.1% | +45.6% | +3.9% | |
| Q4 2025 | +30.1% | +1.6% | -25.9% | |
| Q3 2025 | -1.6% | -9.4% | -8.4% | |
| Q2 2025 | -0.9% | -10.1% | -18.5% | |
| Q1 2025 | -17.8% | -21.4% | +192.4% | |
| Q4 2024 | +36.6% | +68.6% | +51.0% | |
| Q3 2024 | -15.3% | -6.7% | +57.7% | |
| Q2 2024 | +4.2% | +18.2% | +65.1% | |
| Q1 2024 | -4.0% | -6.7% | +12.8% | |
| Q4 2023 | +1.8% | +2.9% | -35.1% | |
| Q3 2023 | -3.4% | -16.4% | -36.8% | |
| Q2 2023 | -1.8% | -5.5% | -1.8% | |
| Q1 2023 | -6.0% | -7.8% | -7.8% | |
| Q4 2022 | -12.5% | -9.4% | -35.4% | |
| Q3 2022 | -5.9% | -7.5% | -40.8% | |
| Q2 2022 | +9.9% | +24.0% | +6.7% | |
| Q1 2022 | +7.9% | +11.0% | -18.6% | |
| Q4 2021 | +6.0% | -7.5% | +14.8% | |
| Q4 2020 | -1.6% | -3.1% | -2.4% | |
| Q3 2021 | -6.9% | +1.3% | +58.5% | |
| Q2 2021 | +11.4% | +5.9% | -8.6% | |
| Q2 2020 | -2.2% | +7.1% | +17.3% | |
| Q1 2021 | -0.7% | +2.3% | -2.3% | |
| Q1 2020 | -4.3% | -4.6% | -17.6% | |
| Q4 2019 | +4.8% | +2.5% | -2.8% | |
| Q3 2020 | +4.5% | +12.4% | +28.6% | |
| Q2 2019 | +4.8% | -4.8% | -4.0% | |
| Q1 2019 | +15.5% | +2.6% | +31.3% | |
| Q4 2018 | -0.9% | +4.4% | +8.9% | |
| Q3 2018 | -1.2% | -0.3% | -11.4% | |
| Q2 2018 | +0.7% | +1.0% | -8.2% | |
| Q1 2018 | +0.9% | -0.7% | -2.1% | |
| Q4 2017 | +29.5% | +32.5% | +20.5% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2017 | +0.0% | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro